

BIOBUSINESS DEMYSTIFIED

# Biopreneurs : The Molecular Millionaires

A biotechnology guide for VCs, Investors, Biotech Executives & Scientists

By

Dr. Ryan Baidya, PhD, MBA

with

Miyuki Shiratani, MBA



Success

Positive

Energy

Positive

Effort

Positive

Thinking

THE BUSINESS BEHIND THE SCIENCE

BIOPRENEUR:  
*The Molecular Millionaires*

# **Biopreneur:** **The Molecular Millionaires**

---

**Ryan Baidya, PhD, MBA**  
California Takshila University

with

**Miyuki Shiratani, MBA**  
Devicenet USA, Inc.



**California Takshila University Press**  
Silicon Valley California

# **Biopreneur:**

## **The Molecular Millionaires**

---

Published by California Takshila University  
Silicon Valley, California

Copyright © 2008 Ryan Baidya  
First Edition

All rights reserved. No part of this book may be reprinted or reproduced or translated or utilized in any form or by any electronic, mechanical or other means, now known or hereafter invented, including photocopying and recording, or in any storage or retrieval system, without written permission from the publisher.

**Library of Congress Cataloging-in-publication Data**  
is available from the United States Library of Congress.

ISBN -10: 0-9822001-0-2 (hbk)  
ISBN-13: 978-0-9822001-0-0 (hbk)  
ISBN-10: 0-9822001-1-0 (pbk)  
ISBN-13: 978-0-9822001-1-7 (pbk)

## Bio-business – a new Gold Rush

Bio-business comprises over 10 trillion dollars or 30 percent of the global economy. Countries throughout the world have identified new opportunities in the bio-business arena as the next hot-technology area and are investing in training their scientists, setting up state-of-the-art life science and technology-knowledge clusters, establishing viable biotechnology industries to fuel growth in bio-business areas.

In the recent years, there is more willingness and push for cross-disciplinary work and ventures between high-tech and biotech. Professional and business investors may find biotech



as a new Gold Rush of our time. Biotech offers infinite opportunities as long as human beings reside on this planet.

It is considered that the bio-business is going to be the fastest growing sector of the world economy during this century. Some even designate the 21st century as the *bio-century*.

*Can you afford to be simply a spectator?*

## About the Authors

---

### **Ryan Baidya, Ph.D., MBA**



Dr. Baidya, an entrepreneur, has a rare combination of expertise and professional background. He is a business strategist, an inventor, a public speaker, a thought leader (Frost & Sullivan), an educator (MBA-faculty for CTU), a mentor and an expert in bio-business. He has overall 15+ years of experience in the biotech and IT -business development (domestic & International), licensing and marketing. He serves as an advisor to several technology-based companies in USA, Japan and India.

Currently, he is a faculty for MBA at the California Takshila University, Silicon Valley. He gave numerous lectures on entrepreneurship; business-strategy and technology related topics at conferences, primarily in USA, and Japan and served as a Thought Leader, Frost & Sullivan Executive Summits. He authored articles, patents, and commentaries.

Dr. Baidya received an MBA at the San Jose State University; a doctoral degree in Science at the University of California, Santa Cruz; and a Master Degree from the Indian Institute of Technology (IIT) Kanpur. As a fellow of the Damon Runyon Walter-Winchell Foundation he spent five years at the University of Colorado Boulder.

### **Miyuki Shiratani, MBA**



Mrs. Shiratani is a logistician with 12+ years of experience in business development and international business relation. She has worked several multinational companies in Japan and USA. Her early works include international business logistics and corporate communications in the high-tech field (Sharp Corp, Japan). Later she contributed immensely in the business development of BioZak, Inc., an antiviral drug discovery company and has written on bio-businesses in Japan.

She currently works at DeviceNet USA in Silicon Valley and serves as an adjunct faculty of Business at the California Takshila University. Mrs. Shiratani received her BA in International Relation in Osaka, Japan and an MBA at San Jose State University, California, USA.

## **BRIEF CONTENT**

Chapter I: Entrepreneurship in Biotechnology

Chapter II: Biopreneurs

Chapter III: Understanding the Business of Biotechnology

Chapter IV: Pre-clinical Development

Chapter V: Clinical Development

Chapter VI: Beginning a Bioventure

Chapter VII: Funding for Bioventure

Chapter VIII: Fund Raising

Chapter IX: Valuation

Chapter X: Public Relations & Investor Relations

Chapter XI: Role of Marketing in Biotech Business

Chapter XII: Investment in Biotech Industry

Chapter XIII: Journey of a Biopreneur

Chapter XVI: It's your Call

Chapter XV: Success

Supplements

# TABLE OF CONTENTS

| <b><u>Topic</u></b>                                | <b><u>Pages</u></b> |
|----------------------------------------------------|---------------------|
| <b>1) Prelude</b>                                  | <b>xvii-xix</b>     |
| <b>Entrepreneurship in Biotechnology</b>           |                     |
| <b>2) Chapter I:</b>                               | <b>01-16</b>        |
| Biopreneurship: Entrepreneurship in Biotechnology  | 03                  |
| Crossing the Boundaries                            | 03                  |
| Uncertainty and Biopreneurship                     | 06                  |
| Uncertainty opens the Door for Opportunities       | 08                  |
| Molecular Millionaires                             | 09                  |
| Steps towards Biopreneurship                       | 10                  |
| Most of us dream to be a Biopreneur                | 12                  |
| A Calling                                          | 13                  |
| <b>Biopreneurs</b>                                 |                     |
| <b>3) Chapter II</b>                               | <b>17-33</b>        |
| Who is a <i>Biopreneur</i> ?                       | 19                  |
| Valuable Opinions                                  | 21                  |
| Leadership: It is Expected                         | 23                  |
| A Simple Philosophy                                | 24                  |
| Inside the Minds of <i>Biopreneurs</i>             | 25                  |
| Paths to Success                                   | 27                  |
| Success Redefined                                  | 28                  |
| Summing it Up                                      | 31                  |
| <b>Understanding the Business of Biotechnology</b> |                     |
| <b>4) Chapter III</b>                              | <b>34-50</b>        |
| What is Biotechnology?                             | 37                  |



|                                           |    |
|-------------------------------------------|----|
| History and Development of the Industry   | 37 |
| Characteristics of the Industry           | 39 |
| Understanding the Drug Discovery Process  | 40 |
| Research and Development                  | 41 |
| Efficacy Studies - Animal Model Selection | 43 |
| The Casualty of R&D                       | 44 |
| Future Drug Development Process           | 45 |
| Business Decision-Making Infrastructure   | 46 |
| Conclusion                                | 50 |

## Pre-clinical Development

|                                                                |              |
|----------------------------------------------------------------|--------------|
| <b>5) Chapter IV</b>                                           | <b>51-78</b> |
| Preclinical Development                                        | 55           |
| Drug discovery: A Brief Story                                  | 55           |
| Developability Decision                                        | 57           |
| Establishing Developability                                    | 58           |
| Pre-clinical Development Tasks                                 | 59           |
| Animal Testing                                                 | 62           |
| History in Brief                                               | 63           |
| Types of animals used                                          | 64           |
| Safety Assessment<br>(in using Animals in Preclinical Studies) | 67           |
| Dose Selection                                                 | 68           |
| Pharmacodynamics—Biological Activities                         | 69           |
| <i>Pharmacokinetics and Toxicokinetics</i>                     | 70           |
| Immunogenicity                                                 | 71           |
| Investigational New Drug Application                           | 73           |

## Clinical Development

|                              |               |
|------------------------------|---------------|
| <b>6) Chapter V</b>          | <b>79-117</b> |
| Clinical Research            | 81            |
| What is a Clinical Trial?    | 82            |
| Clinical Trial – the Process | 84            |

|                                                         |    |
|---------------------------------------------------------|----|
| Clinical Proof of Concept                               | 85 |
| A Few Important Notes                                   | 86 |
| Phases/Stages of Clinical Trial                         | 87 |
| Phase I                                                 | 87 |
| Phase II                                                | 89 |
| Phase III                                               | 89 |
| Phase IV                                                | 90 |
| Regulation and Safety of Patient                        | 92 |
| Pre-clinical Safety Assessment                          | 93 |
| Pre-Approval Safety Assessment in Humans                | 93 |
| Safety Assessment during FDA Regulatory Review          | 93 |
| Post-Marketing Safety Supervision                       | 94 |
| Placebo and other sides of a trial                      | 96 |
| Benefits and risks of participating in a clinical trial | 98 |
| What are side effects and adverse reactions?            | 99 |
| Sponsors                                                | 99 |

## Beginning a Bioventure

|                                     |                |
|-------------------------------------|----------------|
| <b>7) Chapter VI</b>                | <b>102-115</b> |
| Business Plan and Business Planning | 105            |
| Business Plan                       | 105            |
| Executive Summary                   | 106            |
| Executive Summary Items             | 106            |
| Mission statement                   | 107            |
| Company description                 | 107            |
| Technology Description              | 107            |
| Market Analysis                     | 108            |
| Competitors and Competitiveness     | 110            |
| Strategy                            | 111            |
| R&D                                 | 112            |
| People and Assumption               | 113            |
| Summary                             | 114            |

## **Funding for Bioventure**

|                                               |                |
|-----------------------------------------------|----------------|
| <b>8) Chapter VII</b>                         | <b>117-134</b> |
| Financing: from Idea to IPO & Beyond          | 119            |
| Financing Bioventure                          | 123            |
| Financing Strategy –From Idea to IPO          | 123            |
| Equity capital                                | 127            |
| Angel Investments                             | 127            |
| Venture Investments                           | 127            |
| Debt Capital                                  | 129            |
| Mezzanine Finance                             | 129            |
| Bank Loans                                    | 129            |
| Convertible Loans                             | 129            |
| Corporate Bonds                               | 130            |
| Government's role on a Bioventure development | 131            |
| Three Strategies –model for bioeconomy        | 132            |
| Vitalization of bioventure businesses         | 133            |

## **Fund Raising**

|                                |                |
|--------------------------------|----------------|
| <b>9) Chapter VIII</b>         | <b>135-148</b> |
| Fund Raising for your Business | 137            |
| Investors                      | 138            |
| Getting Ready for VC Meeting   | 139            |
| VCs – an Introduction          | 140            |
| VC Investment Features         | 143            |
| Last Words                     | 146            |

## **Valuation**

|                                    |                |
|------------------------------------|----------------|
| <b>10) Chapter IX</b>              | <b>149-160</b> |
| VALUATION OF A BIOBUSINESS         | 151            |
| Valuation Methods                  | 153            |
| Comparable/Guideline Method        | 153            |
| Discounted Cash Flow/Income Method | 154            |

|                               |     |
|-------------------------------|-----|
| Risk adjusted discount factor | 156 |
| Company Specific Factors      | 156 |
| Biobusiness Specific Factors  | 158 |

## Public Relations & Investor Relations

|                                            |                |
|--------------------------------------------|----------------|
| <b>11) Chapter X</b>                       | <b>161-172</b> |
| Pitching the Bioventure Business           | 165            |
| Strategic Plan for Media Relations         | 166            |
| Less/Not so Expensive Media Exposure       | 167            |
| Media Tips                                 | 167            |
| Least Cost-effective Events for Bioventure | 170            |
| Expensive Media Exposure                   | 170            |
| Expected Expenditure                       | 171            |
| Communication Assets                       | 171            |
| What are the Communication Assets          | 171            |

## Role of Marketing in Biotech Business

|                                                     |                |
|-----------------------------------------------------|----------------|
| <b>12) Chapter XI</b>                               | <b>175-190</b> |
| Role of Marketing Biotech Business                  | 176            |
| Crossing the Boundaries                             | 177            |
| Marketing begins in our life before we even know it | 178            |
| Basics of Marketing in Bioventure                   | 179            |
| Market Segments                                     | 179            |
| Niche Marketing & Scientists' Crossover             | 180            |
| Niche Marketing Strategy                            | 180            |
| Differential Strategy & Niche Marketing             | 182            |
| Differential Model in Business                      | 183            |
| Fractional Differential Strategy                    | 184            |
| Earlier Differential Strategy                       | 185            |
| Differential Strategy & Time                        | 185            |
| Differential Strategy & Technology                  | 186            |
| Power of "DS" - From dust to Castle                 | 187            |
| Biopreneurs & "DS"                                  | 188            |

|                                                |     |
|------------------------------------------------|-----|
| Biopreneurs and the Transaction Theory of Cost | 188 |
| Conclusion                                     | 189 |

## Investment in Biotech Industry

|                                      |                |
|--------------------------------------|----------------|
| <b>13) Chapter XII</b>               | <b>191-202</b> |
| Investment in the Biotech Industry   | 193            |
| Biobusiness-a new Gold Rush          | 193            |
| Paradigm of biobusiness              | 194            |
| Common senses not common traits      | 195            |
| Which sector offer short-term return | 196            |
| Which sector offers long-term return | 196            |
| How to evaluate biotech companies    | 197            |
| Proprietary expertise                | 198            |
| Robust pipeline and technology       | 198            |
| Appropriate business model           | 199            |
| Strong management                    | 200            |
| Financial resources                  | 200            |
| Market                               | 201            |

## Journey of a Biopreneur

|                                               |                |
|-----------------------------------------------|----------------|
| <b>14) Chapter XIII</b>                       | <b>203-211</b> |
| Beginning of a Journey                        | 205            |
| Understanding the Reality                     | 205            |
| Questions of Biopreneurs                      | 206            |
| Revenue Based business model bound to succeed | 209            |

## It's your Call

|                                         |                |
|-----------------------------------------|----------------|
| <b>15) Chapter XIV</b>                  | <b>212-222</b> |
| Where does the Inequality of Health Lie | 215            |
| Why do Biobusiness                      | 217            |

Biotech business is more than just making money 218

## Success

|                              |                |
|------------------------------|----------------|
| <b>16) Chapter XV</b>        | <b>223-228</b> |
| Success-Definition           | 225            |
| Success-Viewpoints of Others | 225            |
| Know Thyself                 | 228            |

## SUPPLEMENTS

### Supplement –I 233

- ▶ Package of Studies to Assess Developability
- ▶ List of Studies Needed for IND Registration
- ▶ Optional Tests Depending on Phase I/IIa Strategy
- ▶ Clinical Trial Cost and % of Risk

### Supplement –II 239

- ▶ Time-Value-Money & Discounted Cash Flow

### Supplement-III 243

- ▶ Snap Shot of Bio-VC

### Supplement-IV 249

- ▶ Biotech Around the World

# Prelude

We know that every business is related to either inventive or innovative products or services and it must face some ups and downs throughout the phases of its development. Ultimately, and quite fortunately, a stage usually appears in typical development that can offer some comfort and satisfaction to the participants of most business ventures. But purists in any field will advocate neither satisfaction, nor comfort alone, for its own sake. It is dedication, business zeal, will power to prove proficiency, and the unforgettable love of a product that entices most people involved to continue serving business goals. Our focus and our prime concern in this book are to explore *bioventure* and the journey of a *bioventurer*.

Bioventure represents a microcosm of the world at large concentrated into the small word of biological *venture capital*. As far as biopreneurs are concerned we have to define a scenario with a different kind of light—a light of a different color and temperature. It is an interesting and exciting a time for people wanting to appreciate the world of bioventure. And this is plainly because biotechnology, with emergent educational, governmental, and industrial support, is moving toward its wave crest.

We can think of *bioventure* being a sleek aerodynamic car racing on three wheels—technology, management, and capital. Each wheel is extremely sophisticated, and must be taken care of appropriately to drive the car to an ultimate and optimal destination. After spending many years learning and teaching, when I joined the practiced field of authentic business, I realized the need for the proper understanding of those three driving *wheels*. As people from the field of research work, and management, we may be aware of the greater issues related to our own unique areas of interest, but to be a truly

successful biopreneur we must have a commanding grasp on all three driving wheels in our bio-business.

When we look at the world of *bioventure* we find several cases where people intended to invest heavily, but due to a lack of suitable knowledge they decided to shy away. There are instances where companies having a potential to expand their horizons by meeting a mere few necessities—such as patenting their ideas, and technology. Simply having enough information and facts regarding selling intellectual property or research-based material to pharmaceutical establishments may help some budding bioventures to succeed. But insufficient information also causes comparable ventures to lag behind other more aggressive competitors.

When these realizations struck me, I felt there was a lack of one extraordinary item in our immediate area which could solve our collective problems. That extraordinary item was a quality study curriculum that might be of assistance to all people in the field of bioventure. My intent is that this study material must contain substantial information for all—upcoming entrepreneurs, people from the field of management, and suited investors. This would not only to serve getting people from various fields under the one roof—bioventure—but it would also create a feeling of unanimity within bioventure.

Working together has always been a fun for people like us. Now we have the means to create that same fun—multiplied—by networking our talents, invented drugs, and various other biotechnological products. At the same time there could be an additional benefit waiting for each of us involved, in the form of earned capital. In all honesty, that is simply one future that I dream of for *bioventure*. The best possible future relies on greater understanding among the people associated with this business. This will be possible only if we can integrate our knowledge and experience, and operate within each other's respective fields of



expertise. If we can appreciate the views that those among us want to share, and vice versa, then a treasure trove in bioventure is not far off.

Keeping all this in mind I started writing my book. Now the book is ready to begin its journey. I hope it will travel a long way binding a bio-world together for a better, cheerful future in bioventure. As we all know every business has its commercial perspectives, and that is as it must be. But at the same time we must keep our eyes open for the humanitarian views. I have tried to focus on specific parts of bioventure that venture capitalists, or other prospective investors, along with *biopreneurs*, might always bear in mind, so that their actual goals of helping needy people is the foremost issue. And the money will flow if consumers are there to buy the products, and that will happen if we don't forget others needs.

*Our* book is targeted for everyone associated with the field of bioventure. Whether you are preparing to start a business, a potential investor, a person from the field of management, or you are a researcher, I hope you will find reading this book essential. I have tried to say a lot, though I possibly have missed things which I will need to revise in another issue. I invite responses from you so that I can understand what you want, making an ongoing and continued conversation, an enduring process to exchange thoughts on the topic. After all we can build the future world of bioventure together, by pooling our dreams together.

Ryan Baidya  
Miyuki Shiratani

Writing the book, Biopreneurs: The Molecular Millionaires, we, Ryan Baidya and Miyuki Shiratani, have tried to cover the ordinary and extraordinary resources that readers can utilize to understand the biotech industry. While writing the book, we kept in mind those without biotech backgrounds. So, the book does not emphasize dry hard facts from life science subjects, or financial figures from the stock market. It is rather a lucid situational analysis of the biotech industry.

It strives to educate prospective investors in how and why to invest in start-up ventures, and early-stage companies. In addition, it also provides tools, knowledge, and expertise, identifying appropriate times to realize profits in a particular field. In a nutshell, we have earnestly tried to incorporate as much information as possible to make this book your best friend, philosopher and a guide for those people interested in biotechnology.

*“..Vision without action is a daydream.  
Action without vision is a nightmare..”*

